Sirtex announces SIR-Spheres ® portfolio expansion to include the FLEXdose SELECT 3mL vial configuration allowing for more patient-specific Y-90 selective treatment plans WOBURN, Mass. , Aug. 5, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex") , a leading manufacturer of interventional treatment solutions, announced today the launch of its SIR-Spheres ® FLEXdose SELECT Delivery Program, an innovative, new way to offer precise Y-90 selective internal radiation therapy for the treatment of metastatic colorectal cancer.
SIR-Spheres ® FLEXdose SELECT Delivery Program offers unparalleled flexibility by enabling tailored, patient-specific dosing from a single 3mL delivery vial. This program also marks the availability of 3mL SIR-Spheres ® vials, which contain a reduced volume of microspheres (approximately 27 million compared to 44 million in the current 5mL vials). With up to five days pre-calibration available every day of the week, the novel Y-90 delivery program offers a vial of SIR-Spheres ® designed for more selective treatment targeting.
"We're pleased to introduce this latest innovation in Y-90 radioembolization therapy to treat a broader spectrum of tumor burden," said Matt Schmidt , CEO of Sirtex Medical Limited. "The SIR-Spheres ® FLEXdose SELECT Delivery Program reflects our continued focus on listening to the needs of patients and physicians by enabling access to personalized Y-90 resin doses and expedited patient treatments." "I have found the SIR-Spheres ® FLEXdose Program to be extremely helpful in treating my patients on a timely basis," explained Ripal Ghandi , M.
D., a member of the Miami Cardiac & Vascular Institute and Miami Cancer Institute and the course director for the Symposium on Clinical Interventional Oncology. "With this program, I can personalize the Y-90 treatment for each of my patients using a product that is available every day of the week.
I applaud Sirtex for investing resources in SIR-Spheres ® FLEXdose SELECT and providing more options for physicians to optimize treatment strategies for even more patients." The new 3mL SIR-Spheres ® Y-90 resin microspheres vials are available for order at [email protected] . For more information and details on how to incorporate the SIR-Spheres ® FLEXdose SELECT Delivery Program into your practice, please contact Sirtex at [email protected] .
About SIR-Spheres SIR-Spheres ® are a medical device used in selective internal radiation therapy). SIR-Spheres ® are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Caution: Federal ( USA ) law restricts this device for sale by or on the order of a physician.
Consult the Instructions for Use ( www.sirtex.com ) for a complete listing of indications, contraindications, side effects, warnings and precautions .
About Sirtex Sirtex is a global healthcare business with offices in the U.S., Australia , Europe and Asia , working to improve outcomes in people with cancer.
Sirtex's current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres ® Y-90 resin microspheres. For more information, visit www.sirtex.
com . SOURCE Sirtex Medical Inc..
